Leaked ‘Test and Trace’ slides supports views that COVID-19 testing will be here to stay for a while yet despite the progress of COVID-19 vaccines.
Outlining its ‘Countdown to Christmas portfolio’, the summary of the plans show 27 different work-streams in the major project under 5 key headings:
- Reset with local authorities
- Scale – build out & deploy testing capacity
- Speed – deliver step change in ‘as is’ operational key performance indicators & tech service stability
- Rebuild public trust
What does this mean for investors?
The so-called ‘COVID-19’ testing stocks (such as Novacyt, Omega Diagnostics and Avacta) took a bit of a hammering in the news of the Pfizer COVID-19 vaccine and while have bounced back a little, some are still considerably off their highs.
The move to sort out the shambolic Test and Trace system is one which is of a huge cost financially but one which shows the commitment to ongoing testing.
Within workstream ‘2’ as outlined above there is reference to ‘lighthouse labs – deliver new’, ‘care homes and adult social care’ and ‘UK manufacturers – Lamp / LFD’.
Therefore the aforementioned work stream may well have investors believing once more.